The Effect of Mill Type on Two Dry-Granulated Placebo Formulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Mill Type on Two Dry-Granulated Placebo Formulations
The authors evaluate the effect of various mill types on particle-size distribution, flowability, tabletability, and compactibility.


Pharmaceutical Technology
Volume 32, Issue 11, pp. 72-86


Table IV: Microcrystalline cellulose–dibasic calcium phosphate granulation particle-size (μm) and flow properties.
Milling. Both formulations were milled using the 1.0-kg bags of ribbon collected during the roller-compaction process. Because individual bags of ribbon were used and the bypass level was well controlled, it can be assumed that any difference in the postmilling fines level was generated by the milling process and not a result of segregation during handling of the ribbon. Also, because the ribbon sample bags were numbered during roller compaction, the results of each milling trial can be directly compared with ribbon solid fraction, tensile strength, and thickness values. One milling for each formulation was performed using each of the mill types.


Table V: Microcrystalline cellulose–lactose granulation particle size (μm) and flow properties.
One major difference between the conventional mill types and the Gran-U-Lizer was the number of passes necessary to achieve the desired particle-size distribution. The conventional mill type required only one pass to achieve the desired reduction in particle size. The Gran-U-Lizer required several passes using different roller styles, roller speeds, and roller gaps. According to MPE, multiple passes produce a gradual reduction in particle size and thus a low level of fines.


Figure 5: Microcrystalline cellulose–dibasic calcium phosphate placebo particle-size distribution. (AUTHORS)
Granule physical property data. Particle-size distribution. Tables IV and V show the results of laser-diffraction particle-size analysis using a disperser (HELOS/RODOS, Sympatec, Clausthal-Zellerfeld, Germany). The particle-size distributions show that the Gran-U-Lizer produced the largest particle size of all the mills tested. However, all the milled formulations had similar distributions, as demonstrated in Figures 5 and 6. In addition, the distributions for both formulations were broad, regardless of the mill type used.


Figure 6: Microcrystalline cellulose–lactose placebo particle-size distribution. (AUTHORS)
Flowability. The MCC–DCP formulation exhibits excellent flowability across all mill types, while the MCC–lactose formulation exhibits lower (good) flowability, with the exception of the Gran-U-Lizer, which demonstrated excellent flow based on a flow function coefficient value of 10.1 (4). However, the larger particle size of the Gran-U-Lizer granulations did not substantially improve the flowability of either formulation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here